Proprietary Real-time Thrombosis Detection
Blood clots are deadly, costly, and a growing public health problem. In the US alone, it affects nearly a million people and costs more than 5 billion USD per year. Nearly 80% are preventable but fewer than 50% of patients receive appropriate preventive treatment.
01
Sensitive | Specific
Compared with the traditional D-dimer test, our biomarkers can effectively reduce the missed diagnosis rate, especially at the early stage. Moreover, it helps identify the type and location of the lesion, e.g., differentiation of ischemic and hemorrhagic stroke.
02
Accurate | Conclusive
Compared to other commonly used biomarkers that indicates hypercoagulable state or measures fibrin degradation product. Our proprietary biomarkers directly reflect thrombosis formation and stabilization, therefore more accurate and conclusive.
03
Fast | Real-time
Thrombosis monitoring is essential in clinics, including ICU and PICC intubation but the he performance of current tools is not satisfactory. As a robust and cost effective tool, CVDetect will transform the way of thrombosis monitoring in clinical practices.
04
Reliable | Precision
In the treatment of coagulation-related disorders in diseases such as leukemia, our technology ​accurately accesses thrombosis risk and monitors drug response. Therefore, it guides more personalized treatment to reduce cost and avoid unnecessary side-effects.
